Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety of EDV2209 for Patients with Brain Bleeding (Subarachnoid Hemorrhage)

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Subarachnoid Hemorrhage (SAH), which is a type of bleeding that occurs in the space surrounding the brain. The study is investigating a new treatment called EDV2209, which is a solution for injection designed to inhibit certain proteins in the body. The purpose of the study is to determine the safety and tolerability of this treatment in patients who have experienced a non-traumatic SAH.

Participants in the study will receive either the treatment EDV2209 or a placebo. The study is designed to be randomised and double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The treatment will be administered through a method called intracerebroventricular use, which involves delivering the medication directly into the brain's ventricles, the fluid-filled spaces within the brain.

The study will follow participants over a period to monitor their health and any side effects they may experience. Researchers will assess various health indicators, such as vital signs and laboratory results, to ensure the treatment is safe. Additionally, the study will evaluate the clinical outcomes of the participants using scales like the National Institute of Health Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS) to measure recovery and progress. The study aims to provide valuable information about the potential benefits and risks of EDV2209 for patients with SAH.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Eligibility is determined based on specific criteria, including age between 18 and 80 years, a diagnosis of moderate or severe subarachnoid hemorrhage (SAH) confirmed by a CT scan, and symptoms that began less than 8 hours ago.

    Intracerebroventricular access must be obtained within 8 hours from the start of symptoms.

    A World Federation of Neurological Surgeons (WFNS) score between 1 and 5 is required, assessed after SAH diagnosis but before the first dose of the investigational medication.

    Informed consent is obtained from a trial guardian before any trial-related procedures begin.

  2. Step 2

    Administration of investigational medication

    The investigational medication, EDV2209, is administered through intracerebroventricular use. This means it is injected directly into the brain's ventricular system.

    The medication is given in a solution form for injection.

  3. Step 3

    Monitoring and assessments

    The primary focus is on the safety and tolerability of EDV2209. This involves monitoring for any adverse effects, changes in vital signs, and laboratory results.

    Secondary assessments include clinical outcomes measured by various scales such as the National Institute of Health Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS).

    The number of days spent in different care units and hospitals is recorded.

  4. Step 4

    Pharmacokinetic analysis

    Pharmacokinetic studies are conducted to understand how EDV2209 is processed in the body. This includes measuring the concentration of the medication in the blood and cerebrospinal fluid (CSF) at different times.

    Key measurements include the maximum concentration (Cmax), the time it takes to reach this concentration (Tmax), and the area under the concentration-time curve (AUC).

  5. Step 5

    Follow-up and conclusion

    Follow-up assessments are conducted at discharge from neurosurgical care, and on Days 28 and 84 after the SAH event.

    The trial is estimated to conclude by December 14, 2024.

Who can join the trial?

6 criteria

  • Male or female patients aged 18-80 years can participate.
  • Patients must have a **moderate or severe subarachnoid hemorrhage (SAH)**, which is a type of bleeding in the space around the brain. This must be diagnosed with a **CT scan**, a special type of X-ray that gives detailed images of the brain.
  • The SAH should be caused, or suspected to be caused, by a **ruptured saccular aneurysm**, which is a bulging blood vessel in the brain that has burst. Symptoms must have started less than 8 hours ago.
  • **Intracerebroventricular access** must be obtained within 8 hours from the start of symptoms. This means a way to deliver treatment directly into the brain's fluid spaces must be established.
  • A **WFNS score** between 1 and 5 is required. This score is used to assess the severity of the SAH and is determined after the diagnosis but before the first dose of the investigational medication.
  • Informed consent must be obtained from a trial guardian before starting any trial-related procedures. This means someone legally authorized to make decisions for the patient agrees to their participation.

Who cannot join the trial?

4 criteria

  • Patients who have a **subarachnoid hemorrhage (SAH)** caused by an injury cannot participate. A subarachnoid hemorrhage is bleeding in the space around the brain.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who belong to certain clinical trial groups that are not included in this study cannot participate.
  • Patients who are considered part of a vulnerable population, which means they might need special protection or care, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

EDV2209 is a medication being studied for its safety and tolerability in patients who have experienced a subarachnoid hemorrhage, which is a type of bleeding in the brain. This medication is a MEK1/2 inhibitor, which means it works by blocking specific proteins that may be involved in the body's response to this type of brain injury. The goal of using EDV2209 in this trial is to see if it can be safely administered to patients and to understand how well patients tolerate it.

What is already known about the treatment

EDV2209 – EDV2209 is administered orally and is currently being studied in clinical trials to assess its safety and tolerability in patients with subarachnoid hemorrhage (SAH). This medication is in the early stages of research, specifically in a first-in-human trial, and is not yet widely recognized in medical literature. It is primarily intended for use in treating SAH, a condition involving bleeding in the space surrounding the brain. EDV2209 works by inhibiting the MEK1/2 enzymes, which are part of a signaling pathway that can affect cell growth and survival. It is classified as a MEK inhibitor, a type of targeted therapy that interferes with specific molecular targets involved in the disease process.

Investigated diseases

Subarachnoid Hemorrhage – This condition involves bleeding into the space surrounding the brain, often resulting from a ruptured aneurysm. It can lead to a sudden, severe headache, often described as the worst headache ever experienced. Other symptoms may include neck stiffness, nausea, vomiting, and sensitivity to light. As the condition progresses, it can cause confusion, seizures, or loss of consciousness. The bleeding increases pressure on the brain, which can lead to further complications. Immediate medical attention is crucial to manage the effects of the hemorrhage.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-514590-22-00Protocol codeEDV2209_01Estimated enrolment51 patientsSponsorEdvince AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.